360° Coverage : Novo Hiring New Reps, Now They Need Something To Sell

1 Updates
Novo Hiring New Reps, Now They Need Something To Sell

Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming....

Filed under: news

 
 
 

37 weeks ago

Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming. Perhaps the real news here is that Roche actually has anyone left in the unit to layoff. Like everyone else in conventional blood glucose monitoring, Roche has cut costs to the bone as they desperately try and find a buyer for this beleaguered unit.

Compare this news to an article that appeared in Fierce PharmaMarketing which stated:

“When we hear about companies actually hiring reps, that’s news. Given the thousands of sales layoffs over the past several years–and recruiting focused on emerging markets, especially China–staffing up in the U.S. or Europe is out of the ordinary. When that hiring isn’t about a new drug launch, we hardly know what to make of it.

That’s just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S. First, it was in anticipation of the Tresiba launch that didn’t happen in 2013, but last fall, another 350 joined the company. Couple that with 120 new nurse educators, and the Danish drugmaker has expanded its field force by almost 15%.”

Granted the diabetes drug market is not as bad as the diabetes device market, but it won’t be long before it suffers the same fate, which makes this decision by Novo Nordisk (NVO) even stranger and not just from a cost perspective. It’s a well-known fact that the fewer and fewer physicians are actually seeing sales reps. It’s also true that while the physician would like to have control over which drugs they prescribe increasingly this decision is being taken away from the physician and put in the hands of the patients insurance company.

Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples.

Novo’s decision to continue to add reps while the competition is moving in the exact opposite direction would make sense if they actually had something new to sell. Yet with Tresiba delayed at the FDA indefinitely we can’t quite figure out what exactly these people will be doing. This is not like the old days when a company could put an army of reps into the field and see an almost impact on sales growth. Novo already has a well-established and well known product line. So again just what new stories can these reps, the lucky few who actually get to sit down with a physician, say.

Lastly there is the cost issue which is a major issue when one considers that pricing pressure continues to intensify. This move to add reps makes me believe that old habits die hard at Novo as they continue to believe that they will receive premium pricing for the products they make. There continued pursuit to have Tresiba approved in the U.S. is another example of this.

While the FDA is being overly cautious with Tresiba, the fact is even if the drug does eventually make it to market it will have a tough time given it’s likely a generic version of Lantus will be available which will drive prices even lower.

Years ago I warned everyone that the BGM market was transforming itself from a medical device to commodity market where price trumps performance. Unfortunately for BGM companies this prediction came true and as a result they are watching a once prosperous business sink into oblivion. Unable to divest themselves of these units it makes perfect sense they would cut costs to the bone and get whatever they can from these units.

Today we’ve been warning everyone that the diabetes drug market is following this same path and every indicator tells us that this prediction is also coming true. The real question is can a company like Novo avoid the mistakes made by their BGM counterparts.

Can they, unlike their counterparts, adapt to this new environment, see realistically where this market is and more importantly where it is headed?  Their continued pursuit of Tresiba with the FDA and hiring even more reps tells Diabetic Investor that history will be repeating itself. That it won’t be long before that Novo also decides that it’s time to restructure and align costs with the new realities of this market.

We realize this not welcome news to all these new reps but it is unfortunately the way it is.

Source: Forbes Business

 
Update
1

8 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashing the workforce of ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

WHO welcomes approval of Ebola vaccine trial in Switzerland
Geneva, Oct 28 (IANS) The World Health Organisation (WHO) Tuesday welcomed the approval of a Swiss regulatory authority for a trial with an experimental Ebola vaccine at the Lausanne University Hospital.
 
 
Salt-degraded farm soil now equals the size of France
Toronto, Oct 28 (IANS) Every day for more than 20 years, an average of 2,000 hectares of irrigated land in arid and semi-arid areas across 75 countries, including in India, has been degraded by salt, a research has found.
 
 
Radiation exposure ups aggressive thyroid cancer risk
New York, Oct 28 (IANS) Nuclear power plant accidents could be devastating and researchers have now found that exposure to radioactive iodine is associated with more aggressive forms of thyroid cancer.
 
 
French medical personnel who treated Ebola victim free of virus
Paris, Oct 28 (IANS/EFE) Dozens of medical personnel who took care of a French nurse while she was being treated for the Ebola virus disease have finished their observation period and are free of the virus, French health officials said Tuesday.
 
 
 

Latest from the Network

Benedict Cumberbatch: Sherlock can't have sex
Benedict Cumberbatch says Sherlock Holmes doesn't have sex - because he's more interested in crime. The 38-year-old British actor was catapulted to global fame playing a modern version of the fictional detective in the...
Read more on Celebrity Balla
 
Melissa McCarthy was robbed at gunpoint
Melissa McCarthy was robbed at gunpoint when she moved to California. The 'Bridesmaids' actress was working at a dry cleaners on a quiet street in Santa Monica when she first moved to Hollywood to pursue a movie career...
Read more on Celebrity Balla
 
Russell Brand: I wish I was bisexual
Russell Brand wishes he was bisexual. The 39-year-old comedian - who was married to Katy Perry for 14 months until December 2011 - has confirmed he is single at the moment but is keen to experiment more with his...
Read more on Celebrity Balla
 
Woman saves Indian from Bangladeshis' captivity in Baharin
Manama, Oct 28 (IANS) An Indian, allegedly tortured and held hostage in Bahrain by five Bangladeshis for a paltry BHD800 ransom (about $2,000), was rescued with the help of his co-worker, an Indonesian woman, in an...
Read more on Politics Balla
 
Billiards: Bhaskar shocks Gilchrist, joins Advani in semis
Leeds, Oct 28 (IANS) For long the bridesmaid in Indian billiards, Balachandra Bhaskar, the 43-year-old from Bangalore, authored a big upset when he knocked out defending champion Peter Gilchrist 797-586 to enter the...
Read more on Sport Balla
 
WHO welcomes approval of Ebola vaccine trial in Switzerland
Geneva, Oct 28 (IANS) The World Health Organisation (WHO) Tuesday welcomed the approval of a Swiss regulatory authority for a trial with an experimental Ebola vaccine at the Lausanne University Hospital. According to...
Read more on Business Balla
 
Indian in US gets 15 years in jail for backing Hezbollah
New York, Oct 28 (IANS) An Indian citizen residing illegally in the US has been sentenced to 15 years in prison for allegedly trying to provide material support to Hezbollah, a designated foreign terrorist...
Read more on Politics Balla
 
Another body recovered from sunken South Korean ferry
Seoul, Oct 28 (IANS/EFE) South Korean rescue teams Tuesday recovered one of the 10 bodies still missing from the Sewol ferry which sunk off the country's southwest coast April 16 this year leaving 304 people dead, most...
Read more on Politics Balla
 
Iraqi Kurdish force moves to help fight IS militants in Kobane
Baghdad, Oct 28 (IANS) A group of Iraqi Kurdish fighters, known as Peshmerga, headed Tuesday to the Syrian border town of Kobane via Turkey to help local Kurdish people who have been struggling to fend off attacks by...
Read more on Politics Balla
 
Al Qaeda affiliate seizes seven villages in Syria
Beirut, Oct 28 (IANS/EFE) The Nusra Front, Al Qaeda's affiliate in Syria, has seized seven villages in the northern Syrian province of Idlib over the past few hours, the Syrian Observatory for Human Rights reported...
Read more on Politics Balla